Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications
- PMID: 19219860
- DOI: 10.1002/dmrr.937
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications
Abstract
In addition to reducing hyperglycaemia, the metabolic actions of TZDs (pioglitazone and rosiglitazone) in theory might improve the prognosis of patients with type 2 diabetes. However, it appears from recent data that pioglitazone and rosiglitazone have different cardiovascular risk profiles. The scope of this paper is to examine the benefits and risks of pioglitazone and rosiglitazone. Three large clinical studies (DREAM, and ADOPT with rosiglitazone; PROactive with pioglitazone) have recently been reported. A lower annual rate of decline of ss-cell function observed with rosiglitazone in the ADOPT study, compared with metformin and glyburide (glibenclamide), along with a reduced progression to insulin use seen with pioglitazone in the PROactive study, provides evidence that TZDs are effective in treating progressive hyperglycaemia. In PROactive, although the primary endpoint was not met, pioglitazone was associated with a reduction in a secondary composite endpoint of clinical cardiovascular events in high-risk patients with existing macrovascular disease who were already receiving other glycaemic and cardiovascular medications. Further evidence supporting an anti-atherogenic effect of pioglitazone was gained from the PERISCOPE study of carotid intima-media thickness. Recent controversy concerning a possible increased risk of myocardial infarction associated with rosiglitazone has fuelled uncertainty about the risk-benefit profile of this agent. In 2008, an update of an American Diabetes Association-European Association for the Study of Diabetes consensus statement on initiation and adjustment of therapy in patients with type 2 diabetes advised clinicians against using rosiglitazone. Skeletal fractures have recently emerged as a side effect of both TZDs. Available data suggest that cardiovascular benefits observed with pioglitazone might not be a class effect of TZDs.
Copyright (c) 2009 John Wiley & Sons, Ltd.
Similar articles
-
Thiazolidinediones in type 2 diabetes: a cardiology perspective.Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18698014 Review.
-
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.Fundam Clin Pharmacol. 2009 Dec;23(6):675-9. doi: 10.1111/j.1472-8206.2009.00741.x. Epub 2009 Sep 10. Fundam Clin Pharmacol. 2009. PMID: 19744248 Review.
-
The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003. Clin Ther. 2009. PMID: 20110009
-
[Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].Herz. 2007 Feb;32(1):51-7. doi: 10.1007/s00059-007-2843-5. Herz. 2007. PMID: 17323035 Review. German.
-
[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].Rev Med Suisse. 2007 Aug 29;3(122):1876, 1878-83. Rev Med Suisse. 2007. PMID: 17896661 Review. French.
Cited by
-
Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016.J Clin Med. 2020 Nov 6;9(11):3578. doi: 10.3390/jcm9113578. J Clin Med. 2020. PMID: 33172034 Free PMC article.
-
Naturally-Derived Biomaterials for Tissue Engineering Applications.Adv Exp Med Biol. 2018;1077:421-449. doi: 10.1007/978-981-13-0947-2_23. Adv Exp Med Biol. 2018. PMID: 30357702 Free PMC article. Review.
-
Gene expression microarray analysis of the sciatic nerve of mice with diabetic neuropathy.Int J Mol Med. 2015 Feb;35(2):333-9. doi: 10.3892/ijmm.2014.2011. Epub 2014 Nov 26. Int J Mol Med. 2015. PMID: 25435094 Free PMC article.
-
PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.Exp Mol Med. 2013 Nov 29;45(11):e65. doi: 10.1038/emm.2013.112. Exp Mol Med. 2013. PMID: 24287871 Free PMC article.
-
Therapeutic developments in Friedreich ataxia.J Child Neurol. 2012 Sep;27(9):1212-6. doi: 10.1177/0883073812449691. Epub 2012 Jul 12. J Child Neurol. 2012. PMID: 22791549 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous